CL2022000664A1 - Proteínas de fijación multiespecíficas para tratamiento contra el cáncer - Google Patents

Proteínas de fijación multiespecíficas para tratamiento contra el cáncer

Info

Publication number
CL2022000664A1
CL2022000664A1 CL2022000664A CL2022000664A CL2022000664A1 CL 2022000664 A1 CL2022000664 A1 CL 2022000664A1 CL 2022000664 A CL2022000664 A CL 2022000664A CL 2022000664 A CL2022000664 A CL 2022000664A CL 2022000664 A1 CL2022000664 A1 CL 2022000664A1
Authority
CL
Chile
Prior art keywords
proteins
binding proteins
cancer treatment
multispecific binding
compositions
Prior art date
Application number
CL2022000664A
Other languages
English (en)
Inventor
Pankaj Gupta
Priyanka Gupta
Rajkumar Ganesan
Michael Dziegelewski
Susanne Hipp
Paul Adam
Philip Nicholas Gorman
Vladimir H Voynov
Marcio Lasaro
Justin M Scheer
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of CL2022000664A1 publication Critical patent/CL2022000664A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/82—Colon
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La presente invención se refiere a proteínas de fijación a B7H6/CD3 novedosas. La invención también se refiere a ácidos nucleicos que codifican tales proteínas; a métodos para preparar tales proteínas; a células huésped que expresan o son capaces de expresar tales proteínas; a composiciones que comprenden tales proteínas; y a usos de tales proteínas o tales composiciones, en particular, con fines terapéuticos en el campo de las enfermedades cancerosas.
CL2022000664A 2019-10-02 2022-03-18 Proteínas de fijación multiespecíficas para tratamiento contra el cáncer CL2022000664A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP19201200 2019-10-02

Publications (1)

Publication Number Publication Date
CL2022000664A1 true CL2022000664A1 (es) 2023-01-06

Family

ID=68136317

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2022000664A CL2022000664A1 (es) 2019-10-02 2022-03-18 Proteínas de fijación multiespecíficas para tratamiento contra el cáncer

Country Status (19)

Country Link
US (2) US11732045B2 (es)
EP (1) EP4038100A2 (es)
JP (2) JP7387885B2 (es)
KR (1) KR20220075383A (es)
CN (1) CN114641496A (es)
AR (1) AR120138A1 (es)
AU (1) AU2020358893A1 (es)
BR (1) BR112022004047A2 (es)
CA (1) CA3153372A1 (es)
CL (1) CL2022000664A1 (es)
CO (1) CO2022003552A2 (es)
CR (1) CR20220136A (es)
EC (1) ECSP22019193A (es)
IL (1) IL291817A (es)
JO (1) JOP20220079A1 (es)
MX (1) MX2022004042A (es)
PE (1) PE20221412A1 (es)
TW (1) TW202128756A (es)
WO (1) WO2021064137A2 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112023019138A2 (pt) 2021-03-26 2023-10-24 Innate Pharma Proteína multiespecífica, composição farmacêutica, célula recombinante, método de preparação de uma composição de célula nk, composição de células nk, uso de uma proteína ou composição, métodos e uso
US20220388986A1 (en) 2021-04-29 2022-12-08 Boehringer Ingelheim International Gmbh Heterocyclic compounds capable of activating sting
JP2024521405A (ja) 2021-06-09 2024-05-31 イナート・ファルマ・ソシエテ・アノニム Ｎｋｐ４６、サイトカイン受容体、腫瘍抗原およびｃｄ１６ａに結合する多特異性タンパク質
WO2022258691A1 (en) 2021-06-09 2022-12-15 Innate Pharma Multispecific proteins binding to nkg2d, a cytokine receptor, a tumour antigen and cd16a
WO2022258678A1 (en) 2021-06-09 2022-12-15 Innate Pharma Multispecific proteins binding to nkp30, a cytokine receptor, a tumour antigen and cd16a
CN114395043B (zh) * 2021-12-07 2023-07-11 合肥天港免疫药物有限公司 Ncr3lg1抗体及其应用
CN114395047B (zh) * 2021-12-07 2023-11-07 合肥天港免疫药物有限公司 双特异性抗体及其应用
CN114395045B (zh) * 2021-12-07 2023-06-09 合肥天港免疫药物有限公司 B7h6抗体及其应用
WO2024089006A1 (en) 2022-10-26 2024-05-02 Boehringer Ingelheim International Gmbh Heterocyclic compounds capable of activating sting
WO2024089008A1 (en) 2022-10-26 2024-05-02 Boehringer Ingelheim International Gmbh Heterocyclic compounds capable of activating sting
US20240166629A1 (en) 2022-10-26 2024-05-23 Boehringer Ingelheim International Gmbh Heterocyclic compounds capable of activating sting

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US168A (en) 1837-04-17 Improvement in fire-arms
US5731A (en) 1848-08-22 Elisha k
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
DE3785186T2 (de) 1986-09-02 1993-07-15 Enzon Lab Inc Bindungsmolekuele mit einzelpolypeptidkette.
AU634186B2 (en) 1988-11-11 1993-02-18 Medical Research Council Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
DE69305085D1 (de) 1992-08-10 1996-10-31 Alcan Aluminium Ltd Geländer
DE69334258D1 (de) 1992-08-21 2009-02-26 Univ Bruxelles Immunoglobuline ohne Leichtkette
ES2156149T3 (es) 1992-12-04 2001-06-16 Medical Res Council Proteinas de union multivalente y multiespecificas, su fabricacion y su uso.
AU678483B2 (en) 1993-06-03 1997-05-29 Protherics Inc. Antibody fragments in therapy
EP0739981A1 (en) 1995-04-25 1996-10-30 Vrije Universiteit Brussel Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes
CN101684158A (zh) 2001-01-17 2010-03-31 特鲁比昂药品公司 结合域-免疫球蛋白融合蛋白
EP1456410A2 (en) 2001-12-11 2004-09-15 AlgoNomics N.V. Method for displaying loops from immunoglobulin domains in different contexts
NL1019562C2 (nl) 2001-12-13 2003-06-17 Heineken Tech Services Klepsamenstel voor gebruik bij drankafgifte.
US8764654B2 (en) 2008-03-19 2014-07-01 Zin Technologies, Inc. Data acquisition for modular biometric monitoring system
CN103554260A (zh) 2005-10-12 2014-02-05 莫佛塞斯公司 特异性针对人CD38的完全人HuCAL GOLD-衍生治疗抗体的生成和鉴定
CA2971794C (en) 2007-10-04 2020-03-24 Zymogenetics, Inc. B7 family member zb7h6 and related compositions and methods
SI2235064T1 (sl) 2008-01-07 2016-04-29 Amgen Inc. Metoda za izdelavo heterodimernih molekul - protitelesa fc z uporabo elektrostatičnih usmerjevalnih učinkov
FI20090280A (fi) 2009-07-17 2011-01-18 Kone Corp Hissijärjestely ja menetelmä hissikorin liikuttamiseksi hissikuilussa
CN109293768A (zh) 2009-12-23 2019-02-01 艾斯巴技术,爱尔康生物医药研究装置有限责任公司 减少免疫原性的方法
JP6141831B2 (ja) 2011-05-21 2017-06-07 マクロジェニクス，インコーポレーテッド ヒト及び非ヒトｃｄ３に結合可能なｃｄ３結合分子
IL250396B (en) 2011-06-23 2022-06-01 Ablynx Nv Techniques for predicting, detecting, and reducing A-specific protein interference in assays involving single immunoglobulin variable domains
UA118833C2 (uk) 2011-08-17 2019-03-25 Ґлаксо Ґруп Лімітед Одиничний варіабельний домен імуноглобуліну, який зв'язується з tnfr1
AU2012323287B2 (en) 2011-10-10 2018-02-01 Xencor, Inc. A method for purifying antibodies
JP6389166B2 (ja) 2012-05-07 2018-09-12 トラスティーズ・オブ・ダートマス・カレッジ 抗ｂ７−ｈ６抗体、融合タンパク質、及びこれらを使用する方法
JP2015531751A (ja) * 2012-07-23 2015-11-05 ザイムワークス，インコーポレイテッド 選択的対である軽鎖および重鎖を含む免疫グロブリン構築物
CA3016563A1 (en) * 2016-03-21 2017-09-28 Elstar Therapeutics, Inc. Multispecific and multifunctional molecules and uses thereof
CN109310764B (zh) 2016-04-15 2022-01-14 达特茅斯大学理事会 高亲和力b7-h6抗体和抗体片段
LT3458478T (lt) 2016-05-18 2021-02-10 Boehringer Ingelheim International Gmbh Antikūnai prieš pd-1 ir lag-3, skirti vėžio gydymui
TW202016151A (zh) * 2018-06-09 2020-05-01 德商百靈佳殷格翰國際股份有限公司 針對癌症治療之多特異性結合蛋白

Also Published As

Publication number Publication date
MX2022004042A (es) 2022-05-02
EP4038100A2 (en) 2022-08-10
JP2024020414A (ja) 2024-02-14
IL291817A (en) 2022-06-01
WO2021064137A2 (en) 2021-04-08
CA3153372A1 (en) 2021-04-08
PE20221412A1 (es) 2022-09-20
CO2022003552A2 (es) 2022-04-19
AR120138A1 (es) 2022-02-02
US20210107983A1 (en) 2021-04-15
BR112022004047A2 (pt) 2022-05-24
JP7387885B2 (ja) 2023-11-28
ECSP22019193A (es) 2022-04-29
US11732045B2 (en) 2023-08-22
JP2022551081A (ja) 2022-12-07
AU2020358893A1 (en) 2022-03-31
TW202128756A (zh) 2021-08-01
CR20220136A (es) 2022-05-27
CN114641496A (zh) 2022-06-17
JOP20220079A1 (ar) 2023-01-30
WO2021064137A3 (en) 2021-05-14
US20230340130A1 (en) 2023-10-26
KR20220075383A (ko) 2022-06-08

Similar Documents

Publication Publication Date Title
CL2022000664A1 (es) Proteínas de fijación multiespecíficas para tratamiento contra el cáncer
CO2018012374A2 (es) Moléculas de anticuerpo para el tratamiento del cáncer
JOP20200313A1 (ar) أجسام مضادة dll3-cd3 ثنائية الخاصية
MX2020001198A (es) Agentes de union que se unen a ligando 1 de muerte programada (pd-l1) y grupo de diferenciacion 137 (cd137) y uso de los mismos.
MX2019006045A (es) Proteinas triespecificas dirigidas a psma y metodos de uso.
EA202090817A1 (ru) Триспецифические белки и способы их применения
MX2017014908A (es) Proteinas de union triespecificas y metodos de uso.
CR20190276A (es) Nuevos receptores de células t y terapia inmunológica que los utiliza
MX2019011215A (es) Ácidos nucleicos que codifican proteínas asociadas a crispr y usos de los mismos.
CR20190278A (es) Nuevos receptores de células t y terapia inmunológica que los utiliza
BR112017010110A2 (pt) anticorpos contra cd73 e usos do mesmo
MX2021003554A (es) Proteinas de union a dll3 y metodos de uso.
EA201992131A1 (ru) Высокоаффинные специфичные к mage-a1 tcr и их применение
UY38242A (es) Anticuerpos anti-cd33, anticuerpos bioespecíficos anti- cd33/anti-cd3 y usos de éstos
MX2017014083A (es) Polipeptido de fusion anti-cancer.
ECSP15025845A (es) Anticuerpos anti-ceacam5 y usos de éstos
MX2017014716A (es) Polipeptido de fusion anti-cancer.
BR112015017800A2 (pt) moléculas de ligação ao antígeno biespecífica ativadora de célula t, polinucleotídeo, polipeptídeo, vetor, célula hospedeira, método de produção da molécula de ligação ao antígeno biespecífica ativadora de célula t, composição farmacêutica e uso da molécula de ligação ao antígeno biespecífica ativadora de célula t
UY37630A (es) Combinación farmacéutica, kit, célula huésped que la produce y su uso en métodos para el tratamiento del cáncer
CO2019013150A2 (es) Variantes de proteína morfogénica ósea humana 7 (bmp7)
AR115506A1 (es) Proteínas de fijación multiespecífica para el tratamiento del cáncer
WO2022236276A3 (en) Anti-tigit antibodies, anti-cd96 antibodies, and methods of use thereof
EA202090449A1 (ru) Связывающие агенты, связывающие pd-l1 и cd137, и их применение
CO2019006926A2 (es) Nuevos receptores de células t y terapia inmunológica que los utiliza
EA202193035A1 (ru) Материалы и способы для модуляции иммунитета, опосредованного т-клетками